Kurt C. Wheeler
Kurt Wheeler has been Managing Director of Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, Mr. Wheeler was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 25 years of direct investment and industry experience within the healthcare sector.
Mr. Wheeler was founder and CEO of InControl (NASDAQ:INCL), a medical device company sold to Guidant. Prior to founding InControl he was a Principal with the Mayfield Fund focused on healthcare investing. Mr. Wheeler began his career with Elli Lilly & Co.
Mr. Wheeler holds a BA from Brigham Young University, and a MBA from Northwestern University’s Kellogg School.
Mr. Wheeler represents Clarus Ventures on the Board of Directors of Avillion, Globus, Flowonix, SFJ, and Zogenix (NASDAQ:ZGNX). In addition, he is a member of the Board of Directors of Cardiac Dimensions.
Previous directorships include Hemosense (AMEX:HEM) acquired by Inverness Medical, Intrathrerapeutics acquired by Sulzer Medica, Eyetech Pharmaceuticals (NASDAQ:EYET), SenoRx (NASDAQ:SENO) acquired by CR Bard, Neuromed Pharmaceuticals (NASDAQ:ZLCS), and Somaxon Pharmaceuticals (NASDAQ:SOMX).